Back To Search Results

Biochemistry of Platelet Activating Factor

Editor: Vinod Nookala Updated: 4/10/2023 3:00:59 PM


Platelet-activating factor (PAF) is a potent phospholipid mediator that was first described by its ability to cause platelet aggregation and dilation of blood vessels. Now it is also known as a potent mediator of inflammation, allergic responses, and shock. It causes a dramatic inflammation of air passage resulting in asthmalike symptoms. Production of PAF is inducable by toxins from fragments of destroyed bacteria leading to vasodilation and a drop in blood pressure resulting in reduced cardiac output and shock.

Platelets, endothelial cells, macrophages, monocytes, and neutrophils continuously produce PAF in low quantity. PAF acetylhydrolase (PAF-AH), also known as Lipoprotein-associated phospholipase A2 (Lp-PLA2), inactivates the PAF and PAF-like phospholipids, controlling their actions.[1] Its activity increases when specific stimuli activate inflammatory cells. Lp-PLA2 is a biomarker for cardiovascular risk assessment and is associated with unstable atherosclerosis plaques. PAF also correlates with various medical conditions like asthma, stroke, myocardial infarction, certain tumors and cancers, and various other inflammatory conditions.[2]


Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care



All phospholipids, including PAF, have a glycerol backbone. Three carbons of glycerol are named sn-1, sn-2, and sn-3. PAF has an alkyl group at the sn-1 position, acetyl group at the sn-2 position (middle carbon), phosphocholine at the sn-3 position. Alkyl groups at the sn-1 position of PAF produced enzymatically by leukocytes have a mixture of hexadecyl or octadecyl groups (i.e., 1-O-alkyl-2-acetyl sn-glycero-3-phosphocholines). One of the most critical aspects of PAF is its strict structural requirement for receptor binding and recognition by degradative enzymes. The specificity by degradative enzymes is a highly practical requirement because if the degradative enzymes were not specific, they would also hydrolyze structural phospholipids.[3]


There are two pathways to synthesize PAF: Remodeling and de-novo synthesis.

The remodeling pathway starts with a phospholipid called phosphatidylcholine. It involves substituting an acetyl residue for the long-chain fatty acyl residue a the sn-2 of phosphatidylcholine. A trace amount of phosphatidylcholine is present in all cells as a part of the normal plasma membrane. However, in PAF-producing cells such as endothelial cells and neutrophils, phosphatidylcholine content ranges from 10% to 40%.

Biosynthesis through the remodeling pathway has two steps, and it contributes to the bulk of the synthesis of PAF during inflammation. In the first step, phospholipase A2 (PLA2) acts on phosphatidylcholine producing eicosanoid (arachidonic acid) and lysophosphatidylcholine (LPC). In the second and final step, acetyl residue is transferred to LPC by LPC acetyltransferase to produce PAF.

Synthesis of PAF with the remodeling pathway occurs inside the cell on the nuclear membrane or the endoplasmic reticulum. The mechanism of the translocation of PAF from the interior to the exterior is not known. The fate of synthesized PAF depends on the cell type. Endothelial cells and leukocytes display PAF on their cell surface for juxtracrine signaling, whereas monocytes release most of the PAF they produce. Leukocytes can also be triggered to release some of the PAF they produced.

The alternative pathway of PAF synthesis, de novo pathway, mainly contributes to the physiologic levels of PAF needed for normal cellular function and has three steps:

  1. The first step is to transfer acetyl residue onto a phospholipid, alkyl-lyso-glycerophosphate, by the acetyltransferase to form alkyl-acetyl-glycerophosphate. Acetyltransferase in this pathway is different from acetyltransferase in the remodeling pathway.
  2. The second step is the hydrolysis of alkyl-lyso-glycerophosphate to alkyl-acetyl-glycerol by phosphohydrolase.
  3. The final step involves transferring CDP-choline to alkyl-acetyl-glycerol by choline phosphotransferase to form PAF (alkyl-acetyl-glycerophosphocholine).

Under normal circumstances, the synthesis of PAF is maintained at a very low concentration by de novo synthesis, and its synthesis peaks during an inflammatory response through the remodeling pathway. Various agents can stimulate PAF syntheses, including antigen-antibody interactions, collagen, thrombin, and other inflammatory mediators involved in inflammation. 


PAF acetylhydrolases degrades PAF by removal of acetyl group at the sn-2 position to generate lyso-PAF and acetate. There are various isoforms of PAF acetylhydrolase with variable specificity to PAF distributed widely in various tissues, including plasma and blood cells. PAF acetylhydrolases are unique enzymes because they hydrolyze phospholipids with short chains at the sn-2 position, and they can act in the absence of calcium.[4] Their specificity allows them to work independently of calcium and prevents them from hydrolyzing phospholipid components of plasma membranes and lipoproteins.[5]

Issues of Concern

There are three PAF features that the PAF receptor recognizes: ether bond at sn-1, short residue at sn-2, and phosphocholine head group at sn-3. There is a polyunsaturated arachidonoyl residue on the sn-2 position in a precursor molecule of PAF, phosphatidylcholine. It is replaced by alkyl residue during the controlled synthesis of PAF. However, if there is uncontrolled oxidation of this alkyl residue at the sn-2 position, an oxidized phospholipid is generated, and it can act as a potent ligand and agonist of the PAF receptor. These phospholipids are called “PAF-like lipids.”[6]

Any alteration in the structure of PAF significantly reduces its binding to the PAF receptor. If two carbons elongate the acetyl group at the sn-2, the activity of PAF decreases by a factor of 10-100-fold. Any further elongation results in loss of function unless the alkyl group is oxidized. The PAF receptor can accept oxidized PAF even if it has an elongated alkyl group at sn-2 residue. In vivo, uncontrolled free-radical reactions generate large amounts of PAF-like oxidized phospholipids, especially if the injury is prolonged and vigorous.[7] It is especially crucial in syndromes of inflammatory tissue damage such as ischemic and reperfusion injury because these injuries release significant quantities of oxidants. Effects of PAF-like lipids generated locally in large amounts may be difficult to counteract with PAF receptor antagonists without achieving the high concentration of the drug in that area.

LDL particles contain an abundance of PAF-like lipids. These PAF analogs are not synthesized by remodeling or de novo pathways because they have 4-carbon butanoyl residues at sn-2 instead of the acetyl residue found in PAF. Therefore, PAF-like activity by these lipids is due to oxidation. Oxidation of LDL is a well-known trigger for atherosclerosis cascade, and PAF-like biologic activity by the oxidized lipid plays a key role in its pathophysiology.[8] Potential oxidation pathways and products are defined in the lab under a controlled environment. However, it is difficult to define the potential oxidation pathways and products in vivo because intermediates of oxidized lipids are highly unstable and get metabolized quickly.[9]

Isoprostanes are the products of oxidized arachidonate and are currently the best marker of oxidative processes. They are increased in some disease states and can be increased even further by the oxidative stress of cigarette smoking.[10] Isoprostanes are also potent vasoconstrictors and are present in umbilical blood after maternal smoking.[11] Identification of oxidized fragments in vivo is difficult not only because of the numerous isomers but also because PAF-like lipids can induce synthesis of PAF, leading to its accumulation.[12] Isolated oxidized lipids from LDL, which contains a small amount of PAF, when injected into animals can cause edema and activate and recruit inflammatory cells in injected animals. Therefore, PAF and PAF-like lipids may occur individually or in combination, and despite the structural differences between these lipids, functionally, they are equivalent.[13]

Cellular Level

PAF primary role is to mediate intercellular interactions. A variety of cells synthesize it, and it binds to the extracellular receptors of other cells, activating them and causing a change in their phenotypes. There are also intracellular receptors of PAF that are yet to be rigorously characterized.

Intercellular signaling by PAF is best understood in vascular and inflammatory systems. However, PAF also transmits information intercellularly in CNS, endocrine, GI, and other organs. There is tight control over the PAF intercellular-signaling system through several regulatory mechanisms. Some of these mechanisms include controlling synthetic pathways, biologic availability of PAF through spatial regulation of display, expression of PAF receptor on specific cells, desensitization of the receptor, and rapid degradation of PAF by PAF acetylhydrolases found both intracellularly and extracellularly. These mechanisms have evolved to precisely control PAF biologic activities. Therefore, dysregulation or unregulated intercellular signaling can be a mechanism of disease.

PAF has a well-understood role in mediating cell-cell interaction in acute and chronic inflammation in all organs. Endothelial cells and several classes of leukocytes are involved in inflammation. PAF can mediate its effects by acting over short distances in a paracrine fashion or circulating in the blood in an endocrine fashion. It has a short half-life because of Lp-PLA2 activity in the blood, limiting its endocrine mode of action. Acute inflammation experimental models have shown that most of the PAF signaling occurs in a juxtacrine fashion. PAF on the surface of one cell binds to the PAF receptor on the second cell and activates it.[14]

Activation of endothelial cells by histamine or thrombin causes them to express PAF on their surface.[15] P-selectin, a transiently expressed glycoprotein on activated endothelial cells, and PAF have the same kinetics and work in concert for neutrophil activation and adhesion. P-selectin tethers leukocyte and endothelial cells, allowing PAF from endothelial cells to bind with the PAF receptor on leukocytes.[16] The binding of endothelial cells with leukocytes results in a qualitative change in surface adhesive proteins (CD11/CD18 integrins), making them competent to bind to ligands (e.g., ICAM-1) on activated endothelial cells. Also, PAF stimulation induces the development of polarized shape in leukocytes, prime them for enhanced granular secretion, enhances their motility, and causes a redistribution of surface ligands.[17]

Activation of PAF receptors on monocytes leads to increased secretion of monocyte chemotactic protein (MCP-1) and tumor necrosis factor (TNF-alpha). PAF receptor is a G-protein coupled receptor that translates nuclear factor-kappa B (NF-kB), a transcriptional factor, into the nucleus required for expression of MCP-1, TNF-alpha, and other immediate-early genes.[18]

Molecular Level

Because PAF mediates the actions of other signaling molecules, its activity is controlled at the molecular level. One of the ways to control the activity of PAF is the variable expression of the PAF receptor on cell surfaces. PAF receptor gene, located on chromosome 1, has two distinct promotors (PAFR promoters 1 and 2). As a result, there are two PAF receptor transcripts (PAFR transcripts 1 and 2) differentially expressed in human tissues. Peripheral leukocytes and differentiated eosinophilic cell lines express PAFR transcript-1. Heart, lungs, spleen, kidney express PAFR transcript-2.

PAFR transcript-1 is mostly involved in inflammation and pathological processes and is synthesized in response to stimulation by PAF in a positive feedback manner through the activation of NF-kB. PAFR transcript-2 is controlled by various hormones and cytokines such as estrogen, TGF-beta, retinoic acid, or T3. Retinoic acid and thyroid hormone are potent inducers of PAFR transcript-2. Estrogen also increases PAFR transcript-2 levels, and TFG-beta decreases its levels.[19]


PAF is primarily involved in inflammatory reactions and the activation of thrombotic cascades. It exerts its effects through the receptor present on the target cells, resulting in the production of various inflammatory mediators such as prostaglandins, cytokines, and other inflammatory mediators. It also acts in conjunction with these inflammatory mediators in the inflammatory response. It is also known to affect other systems such as cardiovascular, nervous, and respiratory systems.[20] Some of its functions are below:

Liver: PAF actions on the liver results in increased glycogenolysis. The mechanism of induction of breakdown of glycogen is from the hemodynamic effects of PAF rather than enzymatic regulation.[21]

Lungs: PAF induces the production of leukotrienes D4 and C4 in the lungs. As a result, it leads to fluid loss from the microvasculature, a potentially significant event in the outcome of allergic or inflammatory disease. PAF can also cause massive bronchoconstriction. It is also a sensitive regulator of surfactant secretion in type II alveolar cells.[22]

Brain: Studies on rat brain have shown that the production of PAF increases in response to convulsant stimuli and ischemia through activation of the remodeling pathway. Phospholipase A2 (PLA2) is activated by increased intracellular calcium concentration during the ischemic event, and this enzyme carries out the first step of the remodeling pathway. Also, protein kinase C (PKC) is activated due to ischemia and can phosphorylate and activate lysoPAF-acetyltransferase – the second enzyme involved in biosynthesis – fully activating the remodeling pathway. One of the effects of PAF produced within the brain is to accelerate synaptic polyphosphoinositide turnover. It also increases the Na+-Ca2+ exchange in the neurolemma and brain synaptosomes. PAF does not cross BBB, and vascular endothelial cells produce smaller amounts of PAF than aortic endothelial cells resulting in lower PMN adherence to brain endothelial cells. Brain endothelial cells have lower activity of PLA2 and have lower production of prostacyclin (PGI2). PAF and PGI2 have antagonizing activities in many aspects, and their balance is crucial in terms of thrombotic and anti-thrombotic effects, respectively. Therefore, brain endothelial cells have low levels of both PAF and PGI2.[23]

Heart: PAF can have direct or indirect effects on the heart. It can directly modify heart rate and contractility. Indirectly, it can stimulate inflammatory or endothelial cells to produce thromboxane A2 (TXA2), LTs, or TNF-alpha, leading to the same modification. These molecules can cause coronary artery constrictions and can even contribute to arrhythmias.[24][25]

Kidneys: The primary source of PAF in the body is the kidneys. Anephric patients and animals undergone bilateral nephrectomy have undetectable levels of PAF in the blood. The PAF receptors are expressed in the highest amount in the renal cortex and least in the inner medulla. In the nephron, the glomerulus contains the highest PAF receptors. The renal effects of PAF are challenging to measure in vivo due to its systemic hemodynamic effects. PAF decreases blood pressure, circulating volume, and cardiac output. As a result, it causes a decrease in renal plasma flow, glomerular filtration rate (GFR), and urine flow, along with increased renal vasculature resistance. There is also an increase in sodium and potassium reabsorption along the nephron.[26][27]

Reproduction: PAF has an essential role in oocyte maturation and successful outcomes of pregnancy. PAF contributes to the maturation of the oocyte. Immature follicles have a low amount of prostaglandin E2 (PGE2) and interleukin-1 (IL-1). PGE2 and IL-1 inhibit PAH acetylhydrolase. Therefore, fewer amounts of inhibitors result in increased degradation of PAF by the activity of PAF acetylhydrolase in immature follicles. As the follicle matures, PGE2 and IL-1 concentration increase resulting in inhibition of PAF acetylhydrolase and accumulation of PAF. PAF accumulation in the follicular fluid may stimulate the production of progesterone, which causes increased production of the proteolytic enzymes - plasmin and collagenase - for follicular wall connective tissue degradation during ovulation. PAF is also associated with successful outcomes of pregnancy after fertilization. Smooth muscles in the ovary may also contract in response to PAF accumulation resulting in extrusion of the oocyte cumulus cell mass.[28] PAF may enhance spermatozoa motility and fertilization success. It has a stimulatory effect on the centrioles of spermatozoa.[29] It also plays an essential role in sperm motility, acrosome reaction, and fertilization.[30]


The mechanism of action of PAF is complicated because of the wide variety of processes it mediates.[31] The receptor for PAF is a G-protein coupled receptor, and it can couple with different types of G-proteins depending on the tissue. Gq-protein activates the phosphatidylinositol (PLA3) pathway. PAFR Signalling through Gi inhibits the conversion of ATP to cAMP. Decreased cAMP impairs cAMP-dependent calcium pumps and leads to increased intracellular calcium.[32]

Products of phosphatidylinositol metabolism, diacylglycerol (DAG), and inositol triphosphate (IP3) enhance the action of protein kinase C (PKC). DAG directly stimulates PKC and IP3 indirectly through calcium by opening intracellular calcium channels in the endoplasmic reticulum. PKC activation leads to many responses, such as the release of arachidonic acid, eicosanoid production, and phosphorylation of protein tyrosine. Metabolites of arachidonic acids can also open membrane calcium channels. In addition to activating PKC, intracellular calcium can also activate intracellular contractile proteins, phospholipase A2 (PLA2), and many other proteins as well. Activation of PLA2 results in the synthesis of prostaglandins, thromboxane A2, leukotrienes, and other inflammatory mediators. These inflammatory mediators are involved in leukocyte activation, chemotaxis, aggregation of cells and platelets, and generation of reactive oxygen species.[33]

The function of PKC is dependent on the cell type. It can activate regulatory protein through phosphorylation and play a role in regulating surface PAF receptors.[33] In some cells, PKC contributes to physiological processes such as secretion and proliferation. In platelets, protein kinase C activated by PAF can cause a change in shape change, aggregation, and degranulation. PAFR Signalling through Gi inhibits the conversion of ATP to cAMP. Decreased intracellular cAMP impairs cAMP-dependent calcium pumps and leads to increased intracellular calcium in platelets, further enhancing their activation.[32]

Another downstream effect of PAF is the activation of the nuclear factor kappa-beta (NF-kB). NF-kB is a transcriptional factor that controls DNA transcription, cytokine production, and apoptosis. In leukocytes, it is a transcriptional factor for immediate-early genes, including monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-alpha), and vascular endothelial growth factor (VEGF).[18] PAF also induces the expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule (VCAM-1), and other adhesion molecules.[31]

PAF also activates the mitogen-activated protein kinase (MAPK) cascade in some tissues such as corneal epithelium and brain.[34][35] MAP-kinases are serine/threonine-specific protein kinases that regulate many functions of the cells, including gene expression, proliferation, division, differentiation, survival, and cell death.[36]


PAF is not known as the sole mediator of disease in humans. However, it plays a pivotal role in some syndromes and diseases. The activity of PAF and PAF-like lipids is measurable with the activity of lipoprotein-associated phospholipase A2 (Lp-PLA2) or plasma PAF acetylhydrolase.

It is an independent risk marker for cardiovascular disease (CVD). Pro-inflammatory and pro-atherogenic substrates of Lp-PLA2 enhance the expression of this enzyme in macrophages. Therefore, elevated levels might reflect the accumulation of these substrates.[37] The test measures the activity or amount of Lp-PLA2 and can help determine a patient's risk of developing CVD.[38]


PAF is not a sole mediator of diseases, but it has a crucial role in specific syndromes and diseases. Most of these conditions result from increased PAF or PAF-like activity, which can be due to increased production of PAF or decrease degradation of PAF or PAF-like lipids. PAF acetylhydrolase is the key enzyme responsible for PAF degradation. PAF acetylhydrolase (PAF-AH) has two intracellular isoforms (PAF-AH 1 and PAF-AH II) and one extracellular form called lipoprotein-associated phospholipase (Lp-PLA2).

PAH-AH I plays a vital role in brain development, sperm production, amyloid-beta precursor trafficking to lysosomes, cancer pathogenesis, protein trafficking, and sorting, and aspirin metabolism.[39] PAH-AH II protects cells from oxidative stress and is responsible for maintaining cell integrity by degrading the oxidized fragments of phospholipids.[40][41][42][43] It can transacetylase PAF to other lipid mediators modifying its cellular function.[44]

Lipoprotein-associated phospholipase (Lp-PLA2) or plasma platelet-activating factor acetylhydrolase (PAF-AH), is mainly associated with LDL (>80%) and HDL (<20%). However, only <1% of LDL particles contain Lp-PLA2. A small subset of LDL particles with Lp-PLA2 is protective against oxidative inactivation. Oxidants are potent and irreversible inhibitors of Lp-PLA2 activity.[45]

The Lp-PLA2 has two main biological activities. It hydrolyzes and inactivates PAF and hydrolyzes PAF-like oxidized lipids found in oxidized LDL. The latter role is crucial in the pathogenesis of atherosclerosis because it results in the production of two pro-inflammatory mediators: lysophosphatidylcholine (lysoPC) and oxidized nonesterified fatty acid (OxNEFA). The low activity of Lp-PLA2 is also associated with patients with asthma attributed to the higher levels of PAF in those patients.

Epidemiological studies show that Lp-PLA2 activity has a protective role in atherosclerotic lesions. These studies of the Japanese population reveal that 4% of their population has the Lp-PLA2 variant with the loss-of-function V279F mutation. People with V279F variant Lp-PLA2 have a higher risk of stroke, MI (in men only), cardiomyopathy (both dilated and hypertrophic), coronary artery disease, cerebral hemorrhage, atherosclerosis, polycystic ovary syndrome, and asthma. Also, Lp-PLA2 gene transfer with adenovirus has shown that plasma expression of Lp-PLA2 is associated with reduced oxidized LDL accumulation in the arteries.

However, a meta-analysis of 32 prospective studies has shown that Lp-PLA2 activity has a strong positive association with the risk of coronary heart disease (CHD) and stroke. The magnitude of the relationship of Lp-PLA2 is similar to non-HDL cholesterol or systolic blood pressure.[46] The discrepancy between epidemiological studies and clinical studies is related to the pathophysiology of atherosclerosis involving the production of pro-inflammatory mediators. The protective role of Lp-PLA2 is due to PAF hydrolysis. However, its role in atherosclerosis is due to hydrolyzing PAF-like oxidized lipids in LDL.  

When Lp-PLA2 hydrolyzes PAF-like oxidized lipids in LDL, it generates two pro-inflammatory mediators. These are called lysophosphatidylcholine (lysoPC) and oxidized nonesterified fatty acids (OxNEFA), and they promote plaque development. These pro-inflammatory mediators can recruit and activate leukocytes, impair clearance of dead cells, and induce apoptosis. LysoPC and oxFFA bind to G2A, G protein-coupled receptor that is highly expressed by macrophages in atherosclerotic lesions.[47][13] LysoPC is a direct chemoattractant for monocytes, and it also induces the expression of VCAM-1 and ICAM-1 for monocyte adhesion. It causes macrophages and smooth muscles to proliferate and causes endothelial dysfunction in various arteries. OxNEFA can cause platelet aggregation and vasoconstriction.[48] Lp-PLA2 promotes instability of atherosclerotic plaques because vulnerable and ruptured plaques with necrotic core and apoptotic macrophages contain the highest expression of Lp-PLA2. Stable and less advanced plaques do not express Lp-PLA2.

Lp-PLA2 is a reliable plasma biomarker for cardiovascular disease, and its activity is an independent predictor of coronary heart disease in the general population.[48] Animal studies have shown that darapladib, drug inhibiting Lp-PLA2, reduces lypoPC content in lesions in the coronary artery. It also reduced the expression of pro-inflammatory needed for macrophage and T-cell recruitment and functioning.[49][50] Several large-scale phase-III clinical trials showed that darapladib reduced the rate of major coronary events and total coronary events in patients with atherosclerosis. However, it did not reduce the risk of cardiovascular death, stroke, or myocardial infarction.[51]

Increased PAF activity in the lungs is associated with the pathogenesis of asthma. It mediates bronchoconstriction, bronchial hyperreactivity, mucous secretion, and inflammatory cell infiltration. Aerosolized inhaled PAF causes hyperresponsiveness with methacholine challenge in healthy and asthmatic patients. It increases blood flow through poorly ventilated areas in the lungs. Clinical trials in Japan with PAF receptor antagonist, apafant, showed dose-dependent clinical improvement in clinical symptoms in 8-week treatment in patients with mild to moderate asthma.[52]

The deficiency of plasma PAF-AH is associated with the severity of asthma. A V279F polymorphism is a loss-of-function mutation of plasma PAF-AH in the Japanese population, and it is associated with an increased risk of developing asthma and atopy compared to wild type. There are also other genetic mutations associated with polymorphisms of the plasma PAF-AH gene found in German and British individuals.[20]

Clinical Significance

Sepsis: PAF mediates the pathogenesis of severe sepsis. Bacterial endotoxins can induce PAF production resulting in severe hypotension and end-organ damage.[53] Pafase, recombinant PAF-AH (rPAF-AH), was shown to reduce mortality compared to control in patients with severe sepsis in phase IIB trial.[54] However, the phase III trial was terminated after the interim analysis and showed that it did not reduce mortality.[55]

Stroke: Epidemiological studies have shown that PAF-AH deficiency or mutations in PAF-AH may be a genetic risk factor for stroke.[56]

Cancer: PAF is associated with tumors and cancer cells. The receptor density for PAF is more in cancer cells, and PAF receptor antagonists are known to decrease tumor growth.[57]

Intrauterine Insemination: PAF enhances intrauterine insemination pregnancy rates when inoculated with sperm with normal semen parameters.[58] It does not improve pregnancy rates with sperm with mild male factor infertility parameters.[59]

Diabetes: Plasma PAF-AH (Lp-PLA2) levels will elevate in patients with type 2 Diabetes Mellitus compared to patients with dyslipidemia and healthy patients. Statin therapy in diabetic patients decreases plasma PAF-AH activity.[60] The decrease could be due to the anti-atherogenic effects of statins.[61]

Kidney Disease: Excessive PAF production by mesangial cells results in glomerular damage and can cause glomerulosclerosis and proteinuria. When PAF receptors on podocytes are activated, it results in loss of nephrin, decreased production of proteoglycan, and cytoskeletal rearrangements. As a result, anion charge of the glomerular basement membrane decreases and results in proteinuria.[62]

Allergies: PAF also mediates allergic rhinitis symptoms through its vascular effects. Rupatadine is a second-generation antihistamine with anti-PAF activity approved for the treatment of allergic rhinitis and chronic urticaria. It inhibits mast cell activation by inhibiting both histamine and PAF. When compared to antihistamines without anti-PAF activity, rupatadine is more effective in blocking nasal symptoms.[63]



Derewenda ZS, Derewenda U. The structure and function of platelet-activating factor acetylhydrolases. Cellular and molecular life sciences : CMLS. 1998 May:54(5):446-55     [PubMed PMID: 9645224]

Level 3 (low-level) evidence


Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Critical care medicine. 2002 May:30(5 Suppl):S294-301     [PubMed PMID: 12004251]


Snyder F, Fitzgerald V, Blank ML. Biosynthesis of platelet-activating factor and enzyme inhibitors. Advances in experimental medicine and biology. 1996:416():5-10     [PubMed PMID: 9131118]

Level 3 (low-level) evidence


Hattori M, Arai H, Inoue K. Purification and characterization of bovine brain platelet-activating factor acetylhydrolase. The Journal of biological chemistry. 1993 Sep 5:268(25):18748-53     [PubMed PMID: 8360169]

Level 3 (low-level) evidence


Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. The Journal of biological chemistry. 1997 Jul 18:272(29):17895-8     [PubMed PMID: 9218411]

Level 3 (low-level) evidence


Watson AD, Leitinger N, Navab M, Faull KF, Hörkkö S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM, Berliner JA. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. The Journal of biological chemistry. 1997 May 23:272(21):13597-607     [PubMed PMID: 9153208]

Level 3 (low-level) evidence


Marathe GK, Davies SS, Harrison KA, Silva AR, Murphy RC, Castro-Faria-Neto H, Prescott SM, Zimmerman GA, McIntyre TM. Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. The Journal of biological chemistry. 1999 Oct 1:274(40):28395-404     [PubMed PMID: 10497200]


Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. The New England journal of medicine. 1989 Apr 6:320(14):915-24     [PubMed PMID: 2648148]

Level 3 (low-level) evidence


Morrow JD, Chen Y, Brame CJ, Yang J, Sanchez SC, Xu J, Zackert WE, Awad JA, Roberts LJ. The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug metabolism reviews. 1999 Feb:31(1):117-39     [PubMed PMID: 10065368]


Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Annals of the New York Academy of Sciences. 1993 May 28:686():12-27; discussion 27-8     [PubMed PMID: 8512242]


Obwegeser R, Oguogho A, Ulm M, Berghammer P, Sinzinger H. Maternal cigarette smoking increases F2-isoprostanes and reduces prostacyclin and nitric oxide in umbilical vessels. Prostaglandins & other lipid mediators. 1999 Jun:57(4):269-79     [PubMed PMID: 10402220]


Travers JB. Oxidative stress can activate the epidermal platelet-activating factor receptor. The Journal of investigative dermatology. 1999 Mar:112(3):279-83     [PubMed PMID: 10084302]


Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. The Journal of clinical investigation. 1995 Nov:96(5):2322-30     [PubMed PMID: 7593619]

Level 3 (low-level) evidence


Camussi G, Aglietta M, Malavasi F, Tetta C, Piacibello W, Sanavio F, Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. Journal of immunology (Baltimore, Md. : 1950). 1983 Nov:131(5):2397-403     [PubMed PMID: 6415166]

Level 3 (low-level) evidence


Prescott SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proceedings of the National Academy of Sciences of the United States of America. 1984 Jun:81(11):3534-8     [PubMed PMID: 6587368]


Zimmerman GA, McIntyre TM, Prescott SM. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. The Journal of clinical investigation. 1985 Dec:76(6):2235-46     [PubMed PMID: 4077977]


Panés J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. British journal of pharmacology. 1999 Feb:126(3):537-50     [PubMed PMID: 10188959]

Level 3 (low-level) evidence


Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. The Journal of clinical investigation. 1995 May:95(5):2297-303     [PubMed PMID: 7537762]

Level 3 (low-level) evidence


Shimizu T, Mutoh H, Kato S. Platelet-activating factor receptor. Gene structure and tissue-specific regulation. Advances in experimental medicine and biology. 1996:416():79-84     [PubMed PMID: 9131130]

Level 3 (low-level) evidence


Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. Journal of internal medicine. 1995 Jul:238(1):5-20     [PubMed PMID: 7608647]

Level 3 (low-level) evidence


Buxton DB, Fisher RA, Hanahan DJ, Olson MS. Platelet-activating factor-mediated vasoconstriction and glycogenolysis in the perfused rat liver. The Journal of biological chemistry. 1986 Jan 15:261(2):644-9     [PubMed PMID: 3001074]


Voelkel NF, Worthen S, Reeves JT, Henson PM, Murphy RC. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science (New York, N.Y.). 1982 Oct 15:218(4569):286-9     [PubMed PMID: 7123233]

Level 3 (low-level) evidence


Kumar R, Harvey SA, Kester M, Hanahan DJ, Olson MS. Production and effects of platelet-activating factor in the rat brain. Biochimica et biophysica acta. 1988 Nov 25:963(2):375-83     [PubMed PMID: 3196741]

Level 3 (low-level) evidence


Evangelou AM. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins, leukotrienes, and essential fatty acids. 1994 Jan:50(1):1-28     [PubMed PMID: 8146205]

Level 3 (low-level) evidence


Feuerstein G, Rabinovici R, Leor J, Winkler JD, Vonhof S. Platelet-activating factor and cardiac diseases: therapeutic potential for PAF inhibitors. Journal of lipid mediators and cell signalling. 1997 Mar:15(3):255-84     [PubMed PMID: 9041476]

Level 3 (low-level) evidence


Sánchez-Crespo M, Iñarrea P, Alvarez V, Alonso F, Egido J, Hernando L. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. The American journal of physiology. 1983 Jun:244(6):F706-11     [PubMed PMID: 6859262]

Level 3 (low-level) evidence


Schlondorff D, Neuwirth R. Platelet-activating factor and the kidney. The American journal of physiology. 1986 Jul:251(1 Pt 2):F1-11     [PubMed PMID: 3089026]


Narahara H, Tanaka Y, Kawano Y, Miyakawa I, Johnston JM. Platelet-activating factor acetylhydrolase activity in human follicular fluid. Advances in experimental medicine and biology. 1996:416():121-7     [PubMed PMID: 9131137]

Level 3 (low-level) evidence


Wild MD, Roudebush WE. Platelet-activating factor improves intrauterine insemination outcome. American journal of obstetrics and gynecology. 2001 May:184(6):1064-5     [PubMed PMID: 11349157]


Roudebush WE. Role of platelet-activating factor in reproduction: sperm function. Asian journal of andrology. 2001 Jun:3(2):81-5     [PubMed PMID: 11404790]

Level 3 (low-level) evidence


Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? The Journal of clinical investigation. 2001 Feb:107(3):255-64     [PubMed PMID: 11160146]

Level 3 (low-level) evidence


Feinstein MB, Egan JJ, Sha'afi RI, White J. The cytoplasmic concentration of free calcium in platelets is controlled by stimulators of cyclic AMP production (PGD2, PGE1, forskolin). Biochemical and biophysical research communications. 1983 Jun 15:113(2):598-604     [PubMed PMID: 6307295]


Yost CC, Weyrich AS, Zimmerman GA. The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie. 2010 Jun:92(6):692-7. doi: 10.1016/j.biochi.2010.02.011. Epub 2010 Feb 16     [PubMed PMID: 20167241]

Level 3 (low-level) evidence


Bazan HE, Varner L. A mitogen-activated protein kinase (MAP-kinase) cascade is stimulated by platelet activating factor (PAF) in corneal epithelium. Current eye research. 1997 Apr:16(4):372-9     [PubMed PMID: 9134327]

Level 3 (low-level) evidence


DeCoster MA, Mukherjee PK, Davis RJ, Bazan NG. Platelet-activating factor is a downstream messenger of kainate-induced activation of mitogen-activated protein kinases in primary hippocampal neurons. Journal of neuroscience research. 1998 Aug 1:53(3):297-303     [PubMed PMID: 9698157]

Level 3 (low-level) evidence


Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrine reviews. 2001 Apr:22(2):153-83     [PubMed PMID: 11294822]

Level 3 (low-level) evidence


Donato LJ, Meeusen JW, Callanan H, Saenger AK, Jaffe AS. Advantages of the lipoprotein-associated phospholipase A2 activity assay. Clinical biochemistry. 2016 Jan:49(1-2):172-5. doi: 10.1016/j.clinbiochem.2015.09.002. Epub 2015 Sep 10     [PubMed PMID: 26365697]


De Stefano A, Mannucci L, Massoud R, Bernardini S, Cortese C. Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population. Biochemia medica. 2017 Oct 15:27(3):030701. doi: 10.11613/BM.2017.030701. Epub 2017 Aug 28     [PubMed PMID: 28900364]


Zhou G, Marathe GK, Willard B, McIntyre TM. Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. The Journal of biological chemistry. 2011 Oct 7:286(40):34820-9. doi: 10.1074/jbc.M111.267161. Epub 2011 Aug 15     [PubMed PMID: 21844189]


Mulvihill MM, Benjamin DI, Ji X, Le Scolan E, Louie SM, Shieh A, Green M, Narasimhalu T, Morris PJ, Luo K, Nomura DK. Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity. Chemistry & biology. 2014 Jul 17:21(7):831-40. doi: 10.1016/j.chembiol.2014.05.008. Epub 2014 Jun 19     [PubMed PMID: 24954006]


Chang JW, Zuhl AM, Speers AE, Niessen S, Brown SJ, Mulvihill MM, Fan YC, Spicer TP, Southern M, Scampavia L, Fernandez-Vega V, Dix MM, Cameron MD, Hodder PS, Rosen H, Nomura DK, Kwon O, Hsu KL, Cravatt BF. Selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival. ACS chemical biology. 2015 Apr 17:10(4):925-32. doi: 10.1021/cb500893q. Epub 2015 Jan 20     [PubMed PMID: 25602368]

Level 3 (low-level) evidence


Lecointe N, Meerabux J, Ebihara M, Hill A, Young BD. Molecular analysis of an unstable genomic region at chromosome band 11q23 reveals a disruption of the gene encoding the alpha2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) in human lymphoma. Oncogene. 1999 May 6:18(18):2852-9     [PubMed PMID: 10362256]


Kono N, Inoue T, Yoshida Y, Sato H, Matsusue T, Itabe H, Niki E, Aoki J, Arai H. Protection against oxidative stress-induced hepatic injury by intracellular type II platelet-activating factor acetylhydrolase by metabolism of oxidized phospholipids in vivo. The Journal of biological chemistry. 2008 Jan 18:283(3):1628-1636. doi: 10.1074/jbc.M708622200. Epub 2007 Nov 17     [PubMed PMID: 18024956]

Level 3 (low-level) evidence


Lee TC, Ou MC, Shinozaki K, Malone B, Snyder F. Biosynthesis of N-acetylsphingosine by platelet-activating factor: sphingosine CoA-independent transacetylase in HL-60 cels. The Journal of biological chemistry. 1996 Jan 5:271(1):209-17     [PubMed PMID: 8550561]


McCall MR, La Belle M, Forte TM, Krauss RM, Takanami Y, Tribble DL. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility. Biochimica et biophysica acta. 1999 Jan 29:1437(1):23-36     [PubMed PMID: 9931415]


Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (London, England). 2010 May 1:375(9725):1536-44. doi: 10.1016/S0140-6736(10)60319-4. Epub     [PubMed PMID: 20435228]

Level 1 (high-level) evidence


Obinata H, Hattori T, Nakane S, Tatei K, Izumi T. Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. The Journal of biological chemistry. 2005 Dec 9:280(49):40676-83     [PubMed PMID: 16236715]

Level 3 (low-level) evidence


Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert review of molecular diagnostics. 2007 Sep:7(5):511-7     [PubMed PMID: 17892360]


Hu MM, Zhang J, Wang WY, Wu WY, Ma YL, Chen WH, Wang YP. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta pharmacologica Sinica. 2011 Oct:32(10):1253-8. doi: 10.1038/aps.2011.127. Epub 2011 Aug 15     [PubMed PMID: 21970837]

Level 3 (low-level) evidence


Wang WY, Zhang J, Wu WY, Li J, Ma YL, Chen WH, Yan H, Wang K, Xu WW, Shen JH, Wang YP. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PloS one. 2011:6(8):e23425. doi: 10.1371/journal.pone.0023425. Epub 2011 Aug 31     [PubMed PMID: 21909350]

Level 3 (low-level) evidence


Prasad M, Lennon R, Barsness GW, Prasad A, Gulati R, Lerman LO, Lerman A. Chronic inhibition of lipoprotein-associated phospholipase A(2) does not improve coronary endothelial function: A prospective, randomized-controlled trial. International journal of cardiology. 2018 Feb 15:253():7-13. doi: 10.1016/j.ijcard.2017.09.171. Epub     [PubMed PMID: 29306475]

Level 1 (high-level) evidence


Tamura G, Takishima T, Mue S, Makino S, Itoh K, Miyamoto T, Shida T, Nakajima S. Effect of a potent platelet-activating factor antagonist, WEB-2086, on asthma. A multicenter, double-blind placebo-controlled study in Japan. Advances in experimental medicine and biology. 1996:416():371-80     [PubMed PMID: 9131176]

Level 1 (high-level) evidence


Ishii S, Kuwaki T, Nagase T, Maki K, Tashiro F, Sunaga S, Cao WH, Kume K, Fukuchi Y, Ikuta K, Miyazaki J, Kumada M, Shimizu T. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. The Journal of experimental medicine. 1998 Jun 1:187(11):1779-88     [PubMed PMID: 9607919]

Level 3 (low-level) evidence


Schuster DP, Metzler M, Opal S, Lowry S, Balk R, Abraham E, Levy H, Slotman G, Coyne E, Souza S, Pribble J, Pafase ARDS Prevention Study Group. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Critical care medicine. 2003 Jun:31(6):1612-9     [PubMed PMID: 12794395]

Level 1 (high-level) evidence


Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J, Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Critical care medicine. 2004 Feb:32(2):332-41     [PubMed PMID: 14758145]

Level 1 (high-level) evidence


Satoh K. [Plasma platelet-activating factor acetylhydrolase (PAF-AH) deficiency as a risk factor for stroke]. Brain and nerve = Shinkei kenkyu no shinpo. 2008 Nov:60(11):1319-24     [PubMed PMID: 19069165]


Jancar S, Chammas R. PAF receptor and tumor growth. Current drug targets. 2014:15(10):982-7     [PubMed PMID: 25182608]


Roudebush WE, Toledo AA, Kort HI, Mitchell-Leef D, Elsner CW, Massey JB. Platelet-activating factor significantly enhances intrauterine insemination pregnancy rates in non-male factor infertility. Fertility and sterility. 2004 Jul:82(1):52-6     [PubMed PMID: 15236989]

Level 1 (high-level) evidence


Baka S, Grigoriou O, Hassiakos D, Konidaris S, Papadias K, Makrakis E. Treatment of sperm with platelet-activating factor does not improve intrauterine insemination outcome in unselected cases of mild male factor infertility: a prospective double-blind randomized crossover study. Urology. 2009 Nov:74(5):1025-8. doi: 10.1016/j.urology.2009.06.023. Epub 2009 Aug 29     [PubMed PMID: 19716589]

Level 1 (high-level) evidence


Winkler K,Abletshauser C,Hoffmann MM,Friedrich I,Baumstark MW,Wieland H,März W, Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. The Journal of clinical endocrinology and metabolism. 2002 Dec;     [PubMed PMID: 12466341]

Level 1 (high-level) evidence


Karasawa K. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochimica et biophysica acta. 2006 Nov:1761(11):1359-72     [PubMed PMID: 17049457]

Level 3 (low-level) evidence


Reznichenko A, Korstanje R. The role of platelet-activating factor in mesangial pathophysiology. The American journal of pathology. 2015 Apr:185(4):888-96. doi: 10.1016/j.ajpath.2014.11.025. Epub 2015 Feb 2     [PubMed PMID: 25655028]

Level 3 (low-level) evidence


Mullol J, Bousquet J, Bachert C, Canonica WG, Gimenez-Arnau A, Kowalski ML, Martí-Guadaño E, Maurer M, Picado C, Scadding G, Van Cauwenberge P. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008 Apr:63 Suppl 87():5-28. doi: 10.1111/j.1398-9995.2008.01640.x. Epub     [PubMed PMID: 18339040]

Level 3 (low-level) evidence